Sunday, September 25, 2005

Catching the Eye of Costal VC’s and IB’s

GlobeImmune, Inc. recently announced the successful closing of a Series B stock financing raising $34.3 million, to enable continued development of their two lead Tarmogen™ products in the oncology and infectious disease segments.

The Series B was led by Lilly Ventures along with Medica Venture Partner, Adams Street Partners, Biogen Idec, Inc., Genentech, Inc., Partners Healthcare and GC&H Investments. In addition, all of the A round investors, HealthCare Ventures, LLC, Morgenthaler Ventures and Sequel Venture Partners, also participated.

This brings the September total capital raised in Colorado to nearly $225 million (GlobeImmune, $34.3 million, Replidyne $62.5 million and Myogen $116.4 million). A very good sign indeed, though just scratching the surface of what is yet to come from the Rocky Mountain state.

6 comments:

Anonymous said...
This comment has been removed by a blog administrator.
darrelflynn71385721 said...
This comment has been removed by a blog administrator.
Anonymous said...
This comment has been removed by a blog administrator.
Anonymous said...

This is a good post. I have a site about real estate attorney please look at it if you can.

job opportunitya said...

Incredible blog. I admired your site and I will be
back once again to view it! I use much of my spare
time searching for blogs like yours.
Hey son, you need to check out my plastic surgery seattle blog!

job opportunitya said...

Unusual blog. I liked the site its from so much I
have to visit it again! I surf the web for blogs like
yours in my spare time.
I wish I was like you, but I'll go and peep your blog.